Home > Oncology > ASCO 2020 > Melanoma > Toripalimab plus axitinib effective in metastatic mucosal melanoma

Toripalimab plus axitinib effective in metastatic mucosal melanoma

Presented By
Dr Xinan Sheng, Peking University Cancer Hospital and Institute, China
ASCO 2020
Phase 1
A single-arm, open-label phase 1B study showed that toripalimab plus axitinib was well tolerated, as no dose-limiting toxicities were observed in 6 patients with metastatic mucosal melanoma. Further validation of the efficacy and safety of toripalimab plus axitinib in a phase 3 trial is required. Compared with cutaneous melanoma, mucosal melanoma is a more aggressive malignancy with a high rate of distant metastases. Median overall survival (OS) is less than 12 months and mucosal melanoma appears to be largely resistant to traditional therapies, including immunotherapy. Expression of vascular endothelial growth factor (VEGF) has been shown to be associated with poor outcomes in patients with mucosal melanoma [1]. In the reported phase 1B study, the safety and efficacy of first-line treatment with the VEGFR inhibitor axitinib in combination with the anti-PD1 antibody toripalimab (approved in China for second-line treatment of metastatic melanoma) we...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on